摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,5-嘧啶二甲酸 | 54001-63-7

中文名称
4,5-嘧啶二甲酸
中文别名
4,5-二羧酸嘧啶
英文名称
Pyrimidine-4,5-dicarboxylic acid
英文别名
Pyrimidin-4,5-dicarbonsaeure;4,5-Pyrimidinedicarboxylic acid
4,5-嘧啶二甲酸化学式
CAS
54001-63-7
化学式
C6H4N2O4
mdl
MFCD09910386
分子量
168.109
InChiKey
HZMKWGOYWYBPRV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    454.8±30.0 °C(Predicted)
  • 密度:
    1.665±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.4
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    100
  • 氢给体数:
    2
  • 氢受体数:
    6

安全信息

  • 海关编码:
    2933599090

SDS

SDS:d01703c6d6ca390f3ff66f6f6cb5be43
查看

制备方法与用途

制备方法

医药生物化工中间体。

用途简介

暂无具体内容。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4,5-嘧啶二甲酸 生成 ethyl 8-hydroxy-5-oxo-6H-pyrido[4,3-d]pyrimidine-7-carboxylate
    参考文献:
    名称:
    [EN] NEUROLOGICALLY-ACTIVE COMPOUNDS
    [FR] COMPOSÉS NEUROLOGIQUEMENT ACTIFS
    摘要:
    本发明涉及具有两个融合的6元环,其中第1位置有一个氮原子,第8位置有一个羟基或巯基基团的神经活性化合物,其中至少一个环是芳香环。还公开了制备这些化合物的方法以及它们作为药物或兽药剂的用途,特别是用于治疗神经系统疾病,更具体地说是神经退行性疾病,如阿尔茨海默病。
    公开号:
    WO2004031161A1
  • 作为产物:
    描述:
    二乙基嘧啶-4,5-二羧酸酯sodium hydroxide 作用下, 反应 3.0h, 以90%的产率得到4,5-嘧啶二甲酸
    参考文献:
    名称:
    通过区域特异性置换合成6,9-双[(氨基烷基)氨基]取代的苯并[g]喹喔啉-,苯并[g]喹唑啉-和苯并[g]酞嗪-5,10-二酮
    摘要:
    6,9-二氟取代的苯并[g]喹喔啉-5,10-二酮(3A),苯并[g]喹唑啉-5,10-二酮(3B)和苯并[g]酞嗪-5,10-二酮的合成(3C)已完成。用二胺或N-(叔丁氧基羰基)乙二胺处理3A,3B或3C分别导致与2A,2B和2C有关的相应的6,9-双[(氨基烷基)氨基]取代的类似物。单取代的衍生物4h和4i可以从3A开始的位移中分离出来。嘧啶嘧啶环的竞争性开环与N,N-二甲基乙二胺反应期间发生2C。从2Ac上除去BOC保护基团得到盐酸盐2Ab。开发了一条通往6,9-二羟基苯并[g]-酞嗪-5,10-二酮(21a)的新型合成途径。容易实现21a向二甲苯磺酸酯21b的转化。用N,N-二甲基乙二胺或N-(叔丁氧基羰基)乙二胺处理21b分别导致2Ca和2Cc。从2Cc中除去BOC保护基用三氟乙酸进行离子交换,得到盐酸盐2Cb。用N-(叔丁氧基羰基)乙二胺处理二甲苯磺酸酯21b也导致单取代的类
    DOI:
    10.1002/jhet.5570300624
点击查看最新优质反应信息

文献信息

  • COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS
    申请人:Chodorowski-Kimmes Sandrine
    公开号:US20100239509A1
    公开(公告)日:2010-09-23
    The present patent application relates to a cosmetic or dermatological composition comprising, in a cosmetically or dermatologically acceptable medium, a polymer comprising: (a) a polymer backbone that may be obtained by reaction: of a polyol comprising 3 to 6 hydroxyl groups; of a monocarboxylic acid containing 6 to 32 carbon atoms; of a polycarboxylic acid comprising at least two carboxylic groups COOH, and/or of a cyclic anhydride such as a polycarboxylic acid and/or of a lactone comprising at least one carboxylic group COOH; and (b) at least one junction group linked to the said polymer backbone and capable of establishing H bonds with one or more partner junction groups, each pairing of a junction group involving at least three H (hydrogen) bonds. The patent application also concerns a cosmetic treatment process using the said composition.
    本专利申请涉及一种化妆品或皮肤科学组合物,包括在化妆品或皮肤科学上可接受的介质中,包含以下聚合物的组合物:(a) 由以下反应得到的聚合物骨架:含有3至6个羟基的多元醇;含有6至32个碳原子的一元羧酸;至少含有两个羧基COOH的多元羧酸,和/或类似多元羧酸的环酐和/或至少含有一个羧基COOH的内酯;以及(b) 至少一个连接到所述聚合物骨架的连接基团,并能够与一个或多个配对连接基团建立H键,每个连接基团的配对涉及至少三个H(氢)键。该专利申请还涉及使用所述组合物的化妆品处理过程。
  • COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION
    申请人:GIUSTINIANI Pascal
    公开号:US20090028807A1
    公开(公告)日:2009-01-29
    The present application relates to a cosmetic or pharmaceutical, in particular lipstick, composition comprising a polycondensate The application also relates to a method of cosmetic treatment using the composition, the polycondensate thus defined and a method of preparing the polycondensate.
    本申请涉及一种化妆品或药用品,特别是口红,包括聚缩酸酯的组合物。该申请还涉及一种使用该组合物进行化妆处理的方法,所述聚缩酸酯的定义以及一种制备聚缩酸酯的方法。
  • COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT
    申请人:Malle Gerard
    公开号:US20100272660A1
    公开(公告)日:2010-10-28
    The present application relates to a cosmetic or pharmaceutical composition comprising a polycondensate capable of being obtained by the reaction of the following monomers alone: of 10 to 30% by weight, relative to the total weight of the polycondensate, of one or more polyols comprising 3 to 6 hydroxyl groups; of 30 to 80% by weight, relative to the total weight of the polycondensate, of one or more linear, branched and/or cyclic, saturated or unsaturated, non-aromatic monocarboxylic acids comprising 6 to 32 carbon atoms; of 1 to 40% by weight, relative to the total weight of the polycondensate, of one or more polycarboxylic acids and/or cyclic anhydrides of such a polycarboxylic acid and/or lactones comprising at least one COOH group; and optionally of 0.1 to 15% by weight, relative to the total weight of the polycondensate, of one or more silicones having a hydroxyl and/or carboxyl functional group. The application also relates to a method of cosmetic treatment using the said composition, and the polycondensate thus defined.
    本申请涉及一种化妆品或药用组合物,包括由以下单体反应而得的聚缩酸酯:相对于聚缩酸酯的总重量,占10至30%的一种或多种含有3至6个羟基的多元醇;占30至80%的一种或多种线性、支链和/或环状、饱和或不饱和、非芳香族的单羧酸,含有6至32个碳原子;占聚缩酸酯总重量的1至40%的一种或多种多羧酸和/或多羧酸的环状酐和/或含有至少一个COOH基团的内酯;以及可选地占聚缩酸酯总重量的0.1至15%的一种或多种硅氧烷,具有羟基和/或羧基官能团。该申请还涉及使用所述组合物进行化妆处理的方法,以及如此定义的聚缩酸酯。
  • Prodrugs Based on Gemcitabine Structure and Synthetic Methods and Applications Thereof
    申请人:Xue Xiaoxia
    公开号:US20120088908A1
    公开(公告)日:2012-04-12
    Prodrugs based on gemcitabine structure shown in formula (I) as well as their synthetic method and application are disclosed in the present invention, wherein the definitions for the groups of a, b, c, d, E, Z and V are described in the specification. By modifying the N 4 group, the solubility, the bioavailability and the organ specificity of the prodrugs are improved. Therefore, the fast metabolism problem is overcome for the produced prodrugs compounds. Intestinal toxicity induced by gemcitabine is decreased. Thereby, the prodrugs can be delivered by oral administration in clinics and further improve their anti-tumor, anti-cancer, anti-infection and diffusion preventing capability, and can also specifically act on liver or colon. The synthetic method is simple and adapted to industrial production.
    基于吉西他滨结构的前药,如式(I)所示,以及它们的合成方法和应用在本发明中被揭示,其中a、b、c、d、E、Z和V的定义在说明书中描述。通过修改N4基团,改善了前药的溶解性、生物利用度和器官特异性。因此,生产的前药化合物克服了快速代谢问题。吉西他滨引起的肠道毒性减少。因此,前药可以通过口服在临床中投递,并进一步提高其抗肿瘤、抗癌、抗感染和扩散预防能力,还可以特异性地作用于肝脏或结肠。合成方法简单,适用于工业生产。
  • MODIFIER FOR AROMATIC POLYESTER AND AROMATIC POLYESTER RESIN COMPOSITION COMPRISING THE SAME
    申请人:TABATA Masayoshi
    公开号:US20110224343A1
    公开(公告)日:2011-09-15
    The present invention provides a modifier for aromatic polyesters which enhances the melt fluidity of aromatic polyesters without a significant decrease in the heat resistance of the aromatic polyesters, and an aromatic polyester resin composition including the modifier for aromatic polyesters. The present invention relates to a modifier for aromatic polyesters comprising polyhydric phenol residues and residues of aromatic polycarboxylic acid, acid halide or acid anhydride thereof, and the modifier comprises a material having a structure composed of a first residue selected from the group consisting of divalent residues represented by Formula (I): —Ar—W 1 x —Ar— and by Formula (II): —Ar—, the first residues being bonded to two identical or different second residues selected from the group consisting of monovalent residues represented by Formula (III): and monovalent residues represented by Formula (IV): —O—C(O)—R 7 —.
    本发明提供了一种用于芳香族聚酯的改性剂,可以增强芳香族聚酯的熔融流动性,而不明显降低芳香族聚酯的耐热性,以及包括该改性剂的芳香族聚酯树脂组合物。本发明涉及一种用于芳香族聚酯的改性剂,包括多羟基酚残基和芳香族多羧酸、酸卤或其酸酐残基,该改性剂包括具有以下结构的材料:第一残基,选择自由式(I)所代表的二价残基:—Ar—W1x—Ar—和自由式(II)所代表的:—Ar—,第一残基与选择自由式(III)所代表的单价残基:和自由式(IV)所代表的单价残基:—O—C(O)—R7—的两个相同或不同的第二残基结合。
查看更多